Abstract: Compounds of formula (I): wherein: R1 represents an alkyl, cycloalkyl or cycloalkylalkyl group, R2 represents a linear or branched (C1-C6)alkyl group, and n represents from 1 to 6. Medicaments.

Abstract: Compounds of formula (I): wherein: R1 represents an alkyl, cycloalkyl or cycloalkylalkyl group, R2 and R3, together with the nitrogen atom carrying them, form a heterocycle having from 5 to 8 ring members, and n represents from 2 to 6. Medicinal products containing the same which are useful in treating disorders of the to melatoninergic system.

Abstract: A compound selected from those of formula (I): wherein: R1 represents a group R4 or NHR4, wherein R4 is as defined in the description; R2 represents a substituted linear or branched (C1-C6)alkyl group; R3 represents a hydrogen or halogen atom or a linear or branched (C1-C6)alkyl or linear or branched (C2-C6)alkenyl group. Medicinal products containing the same which are useful in the treatment of disorders of the melatoninergic system.

Abstract: The invention relatests compound of formula (I): wherein: n is 1, 2 or 3, A represents a group X represents N or NR1, R2 represents an alkoxy, cycloalkyloxy or cycloalkylalkyloxy group. and medicinal products containing the same which are useful in treading or in preventing melatoninergic disorder.

Abstract: Compounds of formula (I): wherein: X represents oxygen or sulphur or a group CH2 or R1, R2, R3, R4, R5 and R6 are as defined in the description, A represents an alkylene chain as defined in the description, B represents alkyl or alkenyl substituted by a group ?or R9, or B represents a group ?or R9, D represents a benzene, pyridine, pyrazine, pyrimidine or pyridazine nucleus.

Abstract: Compounds of formula (I): wherein: X represents an oxygen or a sulphur or CH2 or R1 and R2 represent a hydrogen atom, or a group as defined in the description, A represents an alkylene chain as described in the description, B is as defined in the description, R3 and R4 represent a hydrogen atom or a group as defined in the description, D represents an optionally substituted benzene, optionally substituted pyrazine, optionally substituted pyrimidine or optionally substituted pyridazine and medicinal products containing the same which are useful in treating or preventing melatoninergic disorders.

Abstract: Compound of formula (I): wherein: R represents hydrogen or a group selected from alkenyl and optionally substituted alkyl, each of R1 to R8, which may be identical or different, represents hydrogen or a group selected from alkyl, alkenyl, hydroxy, alkoxy, alkenyloxy, arylalkyl, arylalkoxy, carboxy, acyloxy and arylcarbonyloxy, or one of R1 to R8 forms with an adjacent one R1 to R8 an alkylenedioxy group, its optical isomers when they exist, and addition salts thereof with a pharmaceutically acceptable acid or base, with the proviso that: when R does not represent hydrogen, then at least one of R1 to R8 represents hydroxy or acyloxy, and the compounds of formula (I) are other than indeno[1,2-b]indol-10(5H)-one and medicinal products containing the same which are useful for treatment of disorders of the melatoninergic system.

Abstract: The invention relatests compound of formula (I): 1

Abstract: A compound of formula (I): 1

Abstract: Method of treating with compounds of formula (I): wherein: n is 0 or 1, W represents —CO— or S(O)q and q is 0, 1 or 2, G represents a G1, G2, G3 or G4 group as defined in the description, Z represents alkyl, aryl, heteroaryl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylakenyl, heteroarylalkynyl or heteroarylalkyl each optionally substituted, A represents a grouping selected from —A2—, —A1—A2—, —A2—A1—, and —A1—A2—A1— wherein A1 is alkylene and A2 represents phenylene, cycloalkylene, naphthylene or heteroarylene each optionally substituted, R represents hydrogen, alkyl, aryl, heteroaryl, arylalkyl arylalkenyl, arylalkynyl, heteroarylakenyl, heteroarylalkynyl or heteroarylalkyl each optionally substituted, R1 represents alkyl, aryl, heteroaryl, arylalkyl arylalkenyl, arylalkynyl, heteroarylakenyl, heteroarylalkynyl or heteroarylalkyl each optionally substituted, and medicinal products containing the

Abstract: Compounds of formula (I): 1

Abstract: Compound of formula (I): 1

Abstract: Compound of formula (I): wherein: R1, R2, R3, R4, R5, R6 and R8, which may be identical or different, each represents hydrogen, alkyl, arylalkyl, hydroxy, alkoxy, arylalkoxy, acyloxy, arylcarbonyloxy, carboxyalkyl or carboxy, R7 represents hydrogen, hydroxy, alkoxy, arylalkoxy, acyloxy or arylcarbonyloxy group, or one of R1 to R8, together with another of R1 to R8 adjacent to it, forms an alkylenedioxy, its optical isomers, and addition salts thereof with a pharmaceutically acceptable acid or base.

Abstract: Compound of formula (I): 1

Abstract: Compound of formula (I): wherein: n is 0 or 1, W represents —CO— or S(O)q and q is 0, 1 or 2, G represents a G1, G2, G3 or G4 group as defined in the description, Z represents alkyl, aryl, heteroaryl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkenyl, heteroarylalkynyl or heteroarylalkyl each optionally substituted.

Abstract: The invention relates to a compound of formula (I): ##STR1## which can be used as N-myristoyltransferase inhibitors, in which R.sub.1 represents hydrogen, substituted or unsubstituted (C.sub.1 -C.sub.6) alkyl, substituted or unsubstituted phenyl, (C.sub.3 -C.sub.7) cycloalkyl methyl, substituted or unsubstituted (imidazolyl-2-yl)methyl, substituted or unsubstituted (indol-3-yl)methyl or (1-azaindolizin-2-yl)methyl,R.sub.2, R.sub.3, which are identical or different, represent hydrogen or (Cl-C6) alkyl,or when R.sub.1 represents hydrogen, R.sub.2 and R.sub.3 form with the carbon and nitrogen atoms to which they are attached, a mono-, bi- or tricyclic heterocycle,X represents --CO--, --SO.sub.2 --, --PO(OH)--,Y represents --COR.sub.5 or --POR.sub.6 R.sub.6 ',R.sub.4 represents substituted or unsubstituted, linear or branched (C.sub.6 -C.sub.

Abstract: The invention relates to the use of N-myristoyl-(S)-phenylalanine in the treatment of diseases involving myristoylation such as cancer or AIDS.Medicinal products including N-myristoyl-(S)-phenylalanine which are effective for such purpose.